New tests launched in January
In January 2021, Mayo Clinic Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.
The new test that launched in January 2021 by Mayo Clinic Laboratories:
This test is useful for the monitoring of complement blockage by ravulizumab and investigation of suspected alternative pathway complement deficiency, atypical hemolytic uremic syndrome, C3 glomerulonephritis, dense-deposit disease.
In addition to this test, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories: